Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
(2011) The Lancet Oncology — Vol. 12, n° 8, p. 773-784 (2011)
Files
CoiffierBetalAndréMLancetOncol2011.pdf
Restricted Access - Adobe PDF
- 349.9 KB
Details
- Authors
- Abstract
- Johnson & Johnson Pharmaceutical Research & Development and Millennium Pharmaceuticals, Inc.
- Affiliations
Citations
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A., Mayer, J., Offner, F., Rule, S., Teixeira, A., Walewski, J., de Vos, S., Crump, M., Shpilberg, O., Esseltine, D.-L., Zhu, E., Enny, C., Theocharous, P., van de Velde, H., Elsayed, Y. A., & Zinzani, P. L. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology, 12(8), 773-784. https://doi.org/10.1016/S1470-2045(11)70150-4 (Original work published 2011)